Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 1.00 |
| ▸ | PDE4A | P27815 | 13/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 13/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921988 | 0.92 | PDE4B (0.87) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4918255 | 0.92 | PDE4B (1.00) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4916906 | 0.91 | PDE4B (0.87) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4913248 | 0.89 | PDE4B (0.89) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4924655 | 0.88 | PDE4B (0.80) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4916899 | 0.88 | PDE4B (0.82) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4923289 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4924082 | 0.86 | PDE4B (0.79) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4707052 | 0.82 | PDE4B (0.82) | PDE4BPDE4APDE4DALDH1A1KDM4E | |
| SCHEMBL4914580 | 0.82 | PDE4B (0.71) | PDE4BPDE4APDE4DALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | GLAS USA LLC | 2021-02-04 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| WO-2019246317-A9 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | PROGENITY, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2019147824-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PROGENITY, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019036382-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | PROGENITY INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-09-11 | — | — | US | disclosed |
| EP-1913003-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017078-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4D 5/4885 |
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | NR1H2, CBR3, NR4A1 | PDE4B 4185/4885PDE4A 3960/4885PDE4D 4404/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | PDE4B 1544/4885PDE4A 1695/4885PDE4D 2296/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | PDE4B 611/4885PDE4A 559/4885PDE4D 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.